These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2874117)

  • 21. Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile.
    Silke B; Nelson GI; Ahuja RC; Taylor SH
    Postgrad Med J; 1983; 59 Suppl 3():45-52. PubMed ID: 6359109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of labetalol on antipyrine metabolism in the liver].
    Adamska-Dyniewska H; Dziekański S
    Pol Arch Med Wewn; 1984 Mar; 71(3):149-55. PubMed ID: 6739318
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta.
    Brockmeyer NH; Barthel B; Mertins L; Goos M
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):309-11. PubMed ID: 9660037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
    MacCarthy EP; Bloomfield SS
    Pharmacotherapy; 1983; 3(4):193-219. PubMed ID: 6310529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension.
    Erkinaro T; Kavasmaa T; Ylikauma L; Mäkikallio K; Haapsamo M; Acharya G; Ohtonen P; Alahuhta S; Räsänen J
    Reprod Sci; 2009 Aug; 16(8):749-57. PubMed ID: 19380903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine kinetics following tetanus vaccination.
    Descotes J; Simonet R; Evreux JC
    Int J Clin Pharmacol Ther Toxicol; 1986 Nov; 24(11):625-6. PubMed ID: 3793297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
    Chindavijak B; Belpaire FM; De Smet F; Bogaert MG
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1075-9. PubMed ID: 3418510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of labetalol, propranolol and practolol in patients with asthma.
    Larsson K
    Eur J Respir Dis; 1982 May; 63(3):221-30. PubMed ID: 6124442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents.
    Meier J
    Am Heart J; 1982 Aug; 104(2 Pt 2):364-73. PubMed ID: 6125095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
    Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of physical exercise on one-sample antipyrine clearance.
    Fabbri A; Bianchi G; Zoli M; Marchi E; Marchesini G
    Ital J Gastroenterol; 1991 Feb; 23(2):74-6. PubMed ID: 1747507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol.
    Elliott HL; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):573-8. PubMed ID: 6145441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The new beta-adrenergic antagonists.
    Chung DC; Laschuk MJ
    Can Anaesth Soc J; 1984 Jul; 31(4):430-3. PubMed ID: 6146393
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon reduces hepatic drug metabolism in vivo in mice.
    Taylor G; Marafino BJ; Moore JA; Gurley V; Blaschke TF
    Drug Metab Dispos; 1985; 13(4):459-63. PubMed ID: 2863111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The rate of antipyrine metabolism in cancer patients administered specific therapy].
    Bogush TA; Tseĭtlin GIa; Bukhny AF
    Vopr Onkol; 1992; 38(11):1288-93. PubMed ID: 1343156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.